The FDA has approved Bysanti (milsaperidone) tablets for the treatment of bipolar I disorder and schizophrenia in adults. The drug is indicated as a first-line therapy for acute manic or mixed ...
What Is Bysanti, and Why Does It Matter? Bysanti (milsaperidone) is a new FDA-approved oral medicine for treating certain mental health conditions in adults. It belongs to a group of medicines called ...
Antipsychotic medicines are a key part of the pharmacological treatment of schizophrenia. Although they provide therapeutic benefits, they are constrained by well-recognised limitations in terms of ...
LB Pharmaceuticals aims to show that what is old can become new again with a lead drug candidate that’s a modified version of a decades-old schizophrenia medication from Sanofi. The strategy is ...
The last time I spoke about Anavex Life Sciences Corp. (AVXL) just released positive results from its phase 2 ANAVEX3-71-SZ-001 study using ANAVEX 3-71 for the treatment of patients with schizophrenia ...
13d
How Positive Duvakitug IBD Data and New Schizophrenia Drug Filing Will Impact Teva (TEVA) Investors
In February 2026, Sanofi and Teva Pharmaceutical Industries reported positive long-term phase 2b extension results for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results